MNLO News and Press, VYNE Therapeutics From 06/08/20

Since January of this year, shares of Menlo Therapeutics ( MNLO ) (formerly Foamix) have been cut by roughly two-thirds, given the fallout of the Coronavirus pandemic, as well as the lackluster result of the merger between Foamix and Menlo to form the newly combined company. With the failure o...

Shares of Menlo Therapeutics (NASDAQ: MNLO) were sinking 10.4% as of 3:20 p.m. EDT on Friday after dropping as much as 14% earlier in the day. The decline came after the company announced the pricing of a stock offering Friday morning.  Menlo plans to sell 27.05 million shares at $1.85...

Cinedigm (NASDAQ: CIDM ) -24% . More news on: Cinedigm Corp., Dolphin Entertainment, Inc., Titan Medical Inc., Stocks on the move, , Read more ...

Menlo Therapeutics (NASDAQ: MNLO ) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500. More news on: Menlo Therapeutics Inc., Healthcare stocks news, , Stocks on the move, Read more ...

BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an un...

BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to o...

Menlo Therapeutics ( MNLO ) is a biopharma focusing on the development and commercialization of dermatologic products. Its first product to market, Amzeeq, is a topical minocycline foam for the treatment of acne, and now Menlo has a second product, Zilxi for rosacea, that has received FDA appr...

Menlo Therapeutics ( MNLO -4.4% ) announces positive, though mixed, results from a 447-subject Phase 2 clinical trial, Study FX2016-40 , evaluating FCD105 (3% minocycline/0.3% adapalene foam) for the treatment of moderate-to-severe acne vulgaris. More news on: Menlo Therapeutics Inc.,...

BRIDGEWATER, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...